Shaping better lives, one story at a time

Our Stories

Hetero enters into a voluntary licensing agreement with MSD for the manufacturing and distribution of ‘Molnupiravir’, an investigational Oral Therapeutic for the treatment of Covid-19.

In line with the continuous commitment towards the global fight against the ongoing pandemic, Hetero entered into a non-exclusive voluntary licensing agreement with MSD to enable access of Molnupiravir for Covid-19 treatment…

Read More

Affirming our commitment to holistic responsibility on a global level!

Hetero is an organization with true understanding and regard for corporate responsibility. It made conscious efforts over the years to build a value system centered on the aspects of transparency, public accountability, sustainability, human rights, and anti-corruption among others which define a responsible organization…

Read More

Yet another significant stride for Hetero in the battle against Covid-19

Hetero, through its biologics arm ‘Hetero Biopharma’ has been roped in as the manufacturing partner by the Russian Direct Investment Fund (RDIF, Russia’s sovereign wealth fund), for producing Sputnik V - the world’s first registered vaccine against the novel coronavirus infection – in India…

Read More

Hetero’s fight against the pandemic has led to great milestones.

Hetero’s group company Hetero Healthcare has been honoured with the “Covid-19 drug launch excellence award” by Express Pharma for its contribution to providing access to Covifor (Remdesivir) to more than 1,00,000 patients during the most critical Covid-19 phase afflicting the country…

Read More
Explore more

Find out more in our Newsroom